News –
2012
- Terapio has been selected as a participant in the National Institutes of Health’s Accelerated Commercialization Track Program
- Terapio awarded grant from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases.
- Terapio’s RLIP76 protein technology formally invited to participate in the National Institutes of Health’s Nuclear Countermeasures Product Development Program.
2011
- Terapio signs Sponsored Research Agreement with The University of Texas at Austin.
- Dr. Sanjay Awasthi accepts appointment at the City of Hope.
- Terapio signs Research Collaboration Agreement with the laboratory of Dr. Andrew Ellington at The University of Texas at Austin.
2010
- Terapio signs Patent License Agreement with the University of North Texas Health Science Center for exclusive, worldwide rights to intellectual property associated with the RLIP76 protein technology.
- Terapio signs Research Collaboration Agreement with the University of North Texas Health Science Center.
- Terapio signs Research Collaboration Agreement with Texas A&M University System Health Science Center.
